NCI Community Oncology Research Program - Kansas City (NCORP-KC)
NCI Community Oncology Research Program - Kansas City (NCORP-KC)




Breast Clinical Trials

Cancer clinical trials are research studies for developing better ways of detecting, treating, and eventually preventing cancer. By taking part in a clinical trial, you are among the first to receive new research treatments before they are widely available. Your participation in a clinical trial will influence the future direction of cancer care.

 

If you are interested in participating in a clinical trial, consult with your physician. Please note: clinical trials are not risk free. Patients must explore the options that are best for their individuals needs with the help of their physician.



Stage I

NRG-BR003 - "A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer"

CANCER TYPE: Stage I
RESEARCH BASE: NRG
NCT NUMBER: NCT02488967
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
UPDATED ON 01/30/2019 (16:38:53)

BRIEF DESCRIPTION

Breast, female or male, triple neg, node pos or high risk node neg, invasive; adj doxorubicin+cyclophosphamide followed by paclitaxel w/w out carboplatin.  DCP-001 Eligible






NSABP B-51 - "A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy"

CANCER TYPE: Stage I
RESEARCH BASE: CTSU NSABP B-51
NCT NUMBER:
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
UPDATED ON 02/13/2019 (21:29:26)

BRIEF DESCRIPTION

Adj., T1-3 N1, (+) axillary nodes b/f & (-) axillary nodes post-neoadjuv chemo; Eval of post-mastectomy chestwall + reg nodal XRT & post-lumpectomy reg nodal XRT (see RT credentialing requirements in protocol.)  DCP-001 Eligible






SWOG S1418 - "Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy"

CANCER TYPE: Stage I
RESEARCH BASE: SWOG
NCT NUMBER: NCT02954874
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
UPDATED ON 02/22/2019 (21:59:01)

BRIEF DESCRIPTION

TNBC, > 1cm residual invasive breast cancer, or any + LN after neoadjuvant chemotherapy, followed by surgery, PD-L1 evaluation, MK-3475 (pembrolizumab) vs observation.  DCP-001 Eligible






Stage II

Alliance A011401 - "RANDOMIZED PHASE III TRIAL EVALUATING THE ROLE OF WEIGHT LOSS IN ADJUVANT TREATMENT OF OVERWEIGHT AND OBESE WOMEN WITH EARLY BREAST CANCER"

CANCER TYPE: Stage II
RESEARCH BASE: Alliance
NCT NUMBER: NCT02750826
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
UPDATED ON 04/17/2019 (15:29:25)

BRIEF DESCRIPTION

Her2 neg, invasive, post chemo, surgery and RT, health education vs. health education + supervised weight loss intervention.  DCP-001 Eiligible






Alliance A011502 - "A RANDOMIZED PHASE III DOUBLE BLINDED PLACEBO CONTROLLED TRIAL OF ASPIRIN AS ADJUVANT THERAPY FOR NODE POSTIVE HER2 NEGATIVE BREAST CANCER: THE ABC TRIAL"

CANCER TYPE: Stage II
RESEARCH BASE: Alliance
NCT NUMBER: NCT02927249
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
UPDATED ON 01/31/2019 (16:12:26)

BRIEF DESCRIPTION

Breast carcinoma, node positive, HER-2 negative, stage II or III, aspirin 300mg vs. placebo x 5 years. DCP-001 Eligible






ECOG-ACRIN EA1131 - "A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Capecitabine in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy"

CANCER TYPE: Stage II
RESEARCH BASE: ECOG-ACRIN
NCT NUMBER: NCT02445391
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
UPDATED ON 02/22/2019 (19:46:19)

BRIEF DESCRIPTION

Adjuvant, stage II or III, post operative and neoadjuvant chemo, residual triple negative breast ca, platinum based chemo vs capecitabine.  DCP-001 Eligible.






NRG-BR003 - "A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer"

CANCER TYPE: Stage II
RESEARCH BASE: NRG
NCT NUMBER: NCT02488967
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
UPDATED ON 01/30/2019 (16:39:36)

BRIEF DESCRIPTION

Breast, node pos or high risk node neg, triple neg invasive; adj doxorubicin+cyclophosphamide followed by paclitaxel w/w out carboplatin.  DCP-001 Eligible






NRG-BR005 - "A Phase II Trial Assessing the Accuracy of Tumor Bed Biopsies in Predicting Pathologic Response in Patients with Clinical/Radiologic Complete Response after Neoadjuvant Chemotherapy in Order to Explore the Feasibility of Breast Conserving Treatment without Surgery"

CANCER TYPE: Stage II
RESEARCH BASE: NRG
NCT NUMBER: NCT03188393
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
UPDATED ON 05/23/2019 (18:02:03)

BRIEF DESCRIPTION

Invasive ductal ca, stage II and IIIA, how well do tumor bed biopsies predict pathologic response when patient has had complete response to neoadjuvant chemo.






NSABP B-51 - "A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy"

CANCER TYPE: Stage II
RESEARCH BASE: CTSU NSABP-B51
NCT NUMBER:
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
UPDATED ON 02/13/2019 (21:29:55)

BRIEF DESCRIPTION

Adj., T1-3 N1, (+) axillary nodes b/f & (-) axillary nodes post-neoadjuv chemo; Eval of post-mastectomy chestwall + reg nodal XRT & post-lumpectomy reg nodal XRT (see RT credentialing requirements in protocol.)  DCP-001 Eligible






SWOG S1418 - "Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy"

CANCER TYPE: Stage II
RESEARCH BASE: SWOG
NCT NUMBER: NCT02954874
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
UPDATED ON 02/22/2019 (22:08:20)

BRIEF DESCRIPTION

TNBC, > 1cm residual invasive breast cancer, or any + LN after neoadjuvant chemotherapy, followed by surgery, PD-L1 evaluation, MK-3475 (pembrolizumab) vs observation.  DCP-001 Eligible






Stage III

Alliance A011502 - "A RANDOMIZED PHASE III DOUBLE BLINDED PLACEBO CONTROLLED TRIAL OF ASPIRIN AS ADJUVANT THERAPY FOR NODE POSTIVE HER2 NEGATIVE BREAST CANCER: THE ABC TRIAL"

CANCER TYPE: Stage III
RESEARCH BASE: Alliance
NCT NUMBER: NCT02927249
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
UPDATED ON 01/31/2019 (16:12:55)

BRIEF DESCRIPTION

Breast carcinoma, node positive, HER-2 negative, stage II or III, aspirin 300mg vs. placebo x 5 years.  DCP-001 Eligible






ECOG-ACRIN EA1131 - "A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Capecitabine in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy"

CANCER TYPE: Stage III
RESEARCH BASE: ECOG-ACRIN
NCT NUMBER: NCT02445391
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
UPDATED ON 02/22/2019 (19:55:59)

BRIEF DESCRIPTION

Adjuvant, stage II or III, post operative and neoadjuvant chemo, residual triple negative breast ca, platinum based chemo vs capecitabine.  DCP-001 Eligible.






NRG-BR003 - "A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer"

CANCER TYPE: Stage III
RESEARCH BASE: NRG
NCT NUMBER: NCT02488967
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
UPDATED ON 01/30/2019 (16:40:12)

BRIEF DESCRIPTION

Breast, node pos or high risk node neg, triple neg invasive; adj doxorubicin+cyclophosphamide followed by paclitaxel w/w out carboplatin.  DCP-001 Eligible






NRG-BR005 - "A Phase II Trial Assessing the Accuracy of Tumor Bed Biopsies in Predicting Pathologic Response in Patients with Clinical/Radiologic Complete Response after Neoadjuvant Chemotherapy in Order to Explore the Feasibility of Breast Conserving Treatment without Surgery"

CANCER TYPE: Stage III
RESEARCH BASE: NRG
NCT NUMBER: NCT03188393
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
UPDATED ON 05/23/2019 (18:02:35)

BRIEF DESCRIPTION

Invasive ductal ca, stage II and IIIA, how well do tumor bed biopsies predict pathologic response when patient has had complete response to neoadjuvant chemo.






NSABP B-51 - "A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy"

CANCER TYPE: Stage III
RESEARCH BASE: CTSU NSABP B-51
NCT NUMBER:
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
UPDATED ON 02/13/2019 (21:30:25)

BRIEF DESCRIPTION

Adj., T1-3 N1, (+) axillary nodes b/f & (-) axillary nodes post-neoadjuv chemo; Eval of post-mastectomy chestwall + reg nodal XRT & post-lumpectomy reg nodal XRT (see RT credentialing requirements in protocol.)  DCP-001 Eligible






SWOG S1418 - "Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy"

CANCER TYPE: Stage III
RESEARCH BASE: SWOG
NCT NUMBER: NCT02954874
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
UPDATED ON 02/22/2019 (22:08:46)

BRIEF DESCRIPTION

TNBC, > 1cm residual invasive breast cancer, or any + LN after neoadjuvant chemotherapy, followed by surgery, PD-L1 evaluation, MK-3475 (pembrolizumab) vs observation.  DCP-001 Eligible






Stage IV

Alliance A171601 - "A Phase II Trial Assessing the Tolerability of Palbociclib in Combination with Letrozole or Fulvestrant in Patients Aged 70 and Older with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer."

CANCER TYPE: Stage IV
RESEARCH BASE: Alliance
NCT NUMBER: NCT03633331
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
UPDATED ON 01/16/2019 (20:28:47)

BRIEF DESCRIPTION

Stage IV breast ca, ER+, Her2-, 70 or older, Palbociclib + Letrozole or Fulvestrant.  DCP-001 eligible.






NRG-BR002 - "A Phase IIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer"

CANCER TYPE: Stage IV
RESEARCH BASE: NRG
NCT NUMBER: NCT02364557
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
UPDATED ON 09/05/2018 (19:15:10)

BRIEF DESCRIPTION

Stage IV, breast ca, 1-4 metastases, standard of care systemic therapy vs. standard of care systemic therapy + SBRT or surgical ablation of all metastases






SWOG S1416 - "PHASE II RANDOMIZED PLACEBO-CONTROLLED TRIAL OF CISPLATIN WITH OR WITHOUT ABT-888 (VELIPARIB) IN METASTATIC TRIPLE-NEGATIVE BREAST CANCER AND/OR BRCA MUTATION-ASSOCIATED BREAST CANCER"

CANCER TYPE: Stage IV
RESEARCH BASE: SWOG
NCT NUMBER: NCT02595905
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
UPDATED ON 11/20/2018 (19:48:27)

BRIEF DESCRIPTION

Breast, stage IV, triple negative and/or BRCA positive, cisplatin +/- ABT-888 (Veliparib)









  © 2013-2019 All Rights Reserved. Privacy Policy | Terms & Conditions
NCI Community Oncology Research Program - Kansas City (NCORP-KC)
Questions? Call: +1-913-948-5588 | Contact Us
4121 W. 83rd St., Suite 259 Prairie Village, KS 66208 USA